Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2025
0mins
Source: Newsfilter
Collaboration Announcement: Purple Biotech has partnered with the Icahn School of Medicine to research CAPTN-3 antibodies aimed at enhancing tumor-specific immunity by regulating NK and T cells within the tumor microenvironment, potentially improving responses in resistant cancer patients.
Research Focus: The study will investigate how CAPTN-3 alters T and NK cell activation, particularly through the modulation of HLA-E/NKG2A interactions, which may lead to new insights for overcoming resistance to standard immunotherapies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PPBT
Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.639
Low
34.00
Averages
34.00
High
34.00
Current: 0.639
Low
34.00
Averages
34.00
High
34.00
No data
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Purple Biotech Reports Significant Anti-Tumor Activity of CAPTN-3 Platform at ESMO IO 2025
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong efficacy in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and tumor expression of 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, which enhances anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305, targeting TROP2, shows high-affinity binding (EC₅₀ ~2 nM) and potent PBMC-mediated tumor cell killing across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform, particularly in triple-negative breast cancer.
- Future Development Roadmap: Purple Biotech plans to advance CAPTN-3 toward IND-enabling studies in 2026, demonstrating the company's strategic commitment to addressing tumor immune evasion and drug resistance, aiming to capture market opportunities through continuous innovation.
Continue Reading
Purple Biotech Reports New Anti-Tumor Data from CAPTN-3 Platform
- Significant Anti-Tumor Activity: Purple Biotech's CAPTN-3 platform demonstrates substantial anti-tumor activity through its tri-specific antibodies IM1240 and IM1305 across different tumor antigens, particularly showing strong apoptosis induction in PD-1 resistant models, indicating the platform's potential applicability in various solid tumors.
- Key Role of NKG2A Arm: Transcriptomic analysis of approximately 11,000 TCGA samples reveals a strong correlation between NKG2A expression and the expression of tumor antigens 5T4 or TROP2, supporting the inclusion of the NKG2A arm in CAPTN-3 designs, thereby enhancing anti-cancer immune activity, especially in PD-1 resistant patient-derived samples.
- Platform Adaptability Validation: The new candidate IM1305 exhibits high affinity binding to both TROP2 and NKG2A, achieving potent tumor cell killing at low concentrations (EC₅₀ 1-5 pM) across multiple tumor types, further validating the adaptability and broad application potential of the CAPTN-3 platform.
- Future Development Roadmap: Purple Biotech plans to advance the CAPTN-3 platform toward IND-enabling studies in 2026, with CEO Gil Efron emphasizing that the platform's multifunctional mechanisms will help overcome immune evasion challenges in solid tumor treatments, showcasing strong market prospects.
Continue Reading